Highly potent inhibitors of TNF-α production. Part II: Metabolic stabilization of a newly found chemical lead and conformational analysis of an active diastereoisomer

Bioorganic and Medicinal Chemistry

Volumn 10, Issue 12, 2002, Pages 3787-3805

  Matsui, Toshiaki ^a   Kondo, Takashi ^a   Nishita, Yoshitaka ^a   Itadani, Satoshi ^a   Tsuruta, Hiroshi ^a   Fujita, Setsuko ^a   Omawari, Nagashige ^a   Sakai, Masaru ^a   Nakazawa, Shuichi ^a   Ogata, Akihito ^a   Mori, Hideaki ^a   Kamoshima, Wataru ^a   Terai, Kouichiro ^a   Ohno, Hiroyuki ^a   Obata, Takaaki ^a   Nakai, Hisao ^a   Toda, Masaaki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (OCTANOYLAMINO) 2,3 DIHYDRO 1H INDEN 2 YLDISODIUM PHOSPHATE; 1 METHYL 2 (3 METHOXYPHENYL) 2 (OCTANOYLAMINO)ETHYLDISODIUM PHOSPHATE; 1 METHYL 2 [(HEXYLOXYCARBONYL)AMINO] 2 (3 METHOXYPHENYL)ETHYLDISODIUM PHOSPHATE; 2 (3 ISOPROPYLOXYPHENYL) 1 METHYL 2 (OCTANOYLAMINO)ETHYLDISODIUM PHOSPHATE; ANTIINFLAMMATORY AGENT; GALACTOSAMINE; INDAN DERIVATIVE; PREDNISOLONE; PROTEIN SYNTHESIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIASTEREOISOMER; DRUG CONFORMATION; DRUG STRUCTURE; FEMALE; HEPATITIS; MALE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; SHOCK; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG STABILITY; HEPATITIS, TOXIC; INDANS; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MAXIMUM TOLERATED DOSE; MICE; MOLECULAR CONFORMATION; ORGANOPHOSPHORUS COMPOUNDS; RATS; SHOCK, SEPTIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036976021     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00380-2     Document Type: Article

References (23)

1. (a) Camussi G., Lupia E. Drugs. 55:1998;613 (b) Arrieta O., Rodriguez-Reyna T.S., Sotelo J. Exp. Opin. Ther. Patents. 10:2000;601.
2. (a) Camussi G., Lupia E. Drugs. 55:1998;613 (b) Arrieta O., Rodriguez-Reyna T.S., Sotelo J. Exp. Opin. Ther. Patents. 10:2000;601.
3. (a) Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;903 (b) Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;907 (c) Matsui, T.; Kondo, T.; Nishita, Y.; Itadani, S.; Nakatani, S.; Omawari, N.; Sakai, M.; Nakazawa, S.; Ogata, A.; Mori, H.; Terai, K.; Kamoshima, W.; Ohno, H.; Obata, T.; Nakai, H.; Toda, M. Bioorg. Med. Chem. Accepted for publication.
4. (a) Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;903 (b) Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;907 (c) Matsui, T.; Kondo, T.; Nishita, Y.; Itadani, S.; Nakatani, S.; Omawari, N.; Sakai, M.; Nakazawa, S.; Ogata, A.; Mori, H.; Terai, K.; Kamoshima, W.; Ohno, H.; Obata, T.; Nakai, H.; Toda, M. Bioorg. Med. Chem. Accepted for publication.
5. (a) Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;903 (b) Matsui T., Kondo T., Nishita Y., Itadani S., Tsuruta H., Fujita S., Omawari N., Sakai M., Nakazawa S., Ogata A., Mori H., Ohno H., Obata T., Nakai H., Toda M. Bioorg. Med. Chem. Lett. 12:2002;907 (c) Matsui, T.; Kondo, T.; Nishita, Y.; Itadani, S.; Nakatani, S.; Omawari, N.; Sakai, M.; Nakazawa, S.; Ogata, A.; Mori, H.; Terai, K.; Kamoshima, W.; Ohno, H.; Obata, T.; Nakai, H.; Toda, M. Bioorg. Med. Chem. Accepted for publication.
6. (a) Chag H.-T., Sharpless K.B. Tetrahedron Lett. 37:1996;3219 (b) Kolb H.C., VanNieuwenhze M.S., Sharpless K.B. Chem. Rev. 94:1994;2483.
7. (a) Chag H.-T., Sharpless K.B. Tetrahedron Lett. 37:1996;3219 (b) Kolb H.C., VanNieuwenhze M.S., Sharpless K.B. Chem. Rev. 94:1994;2483.
8. (a) Dibenzylphosphorochloridate was prepared from benzyl phenoxymethylphosphinate according to the following paper and used as 1 M stock solution: Kenner, G. W.; Todd, A. R.; Weymouth, F. J. J. Chem. Soc. 1952, 3675. (b) Rasolonjaatovo I., Sarfati S.R. Nucleosides & Nucleotides. 17:1998;2021. and references cited therein (c) Ozaki S., Ling L., Ogasawara T., Watanabe Y., Hirata M. Carbohydr. Res. 259:1994;307.
9. (a) Dibenzylphosphorochloridate was prepared from benzyl phenoxymethylphosphinate according to the following paper and used as 1 M stock solution: Kenner, G. W.; Todd, A. R.; Weymouth, F. J. J. Chem. Soc. 1952, 3675. (b) Rasolonjaatovo I., Sarfati S.R. Nucleosides & Nucleotides. 17:1998;2021. and references cited therein (c) Ozaki S., Ling L., Ogasawara T., Watanabe Y., Hirata M. Carbohydr. Res. 259:1994;307.
10. (a) Dibenzylphosphorochloridate was prepared from benzyl phenoxymethylphosphinate according to the following paper and used as 1 M stock solution: Kenner, G. W.; Todd, A. R.; Weymouth, F. J. J. Chem. Soc. 1952, 3675. (b) Rasolonjaatovo I., Sarfati S.R. Nucleosides & Nucleotides. 17:1998;2021. and references cited therein (c) Ozaki S., Ling L., Ogasawara T., Watanabe Y., Hirata M. Carbohydr. Res. 259:1994;307.
11. Scheit K.-H. Biochim. Biophys. Acta. 157:1968;632.
12. Franke A., Scheit K.-H., Eckstein F. Chem. Ber. 101:1968;2998.
13. Mitsunobu O. Synthesis. 1981;1.
14. Compound 41 was prepared from 3-benzyloxy benzaldehyde according to the following paper: Steiger, R. E. Org. Synth., 1995, III 84.
15. Deuchert K., Hertenstein U., Hünig S. Synthesis. 777:1973.
16. Krepski L.R., Jensen K.H., Heilmann S.M., Rasmussen J.K. Synthesis. 1986;301.
17. Mitsunobu O., Kato K., Kimura J. J. Am. Chem. Soc. 91:1969;6510.
18. Sekut, L.; Yarnall. D.; Stimpson, S. A.; Noel, L. S.; Bateman-Fite, R.; Clark, R. L.; Brackeen M. F.; Menius, J. A.; Connolly, K. M., Jr. Clin. Exp. Immunol. 1995, 100, 126.
19. (b) Furusako, S.; Takahashi, T.; Mori, S.; Takahashi, Y.; Tsuda, T.; Namba, M.; Mochizuki H. Acta. Med. Okayama 2001, 55, 105.
20. (c) Solorzano C.C., Ksontini R., Pruitt J.H., Hess P.J., Edwards P.D., Kaibara A., Abouhamze A., Auffenberg T., Galardy R.E., Vauthey J.N., Copeland E.M. 3rd., Edwards C.K. 3rd., Lauwers G.Y., Clare-Salzler M., MacKay S.L., Moldawer L.L., Lazarus D.D. J. Immunol. 158:1997;414.
21. (d) Tiegs G., Barsig J., Matiba B., Uhlig S., Wendel A. J. Clin. Invest. 93:1994;2616.
22. (e) Barton B.E., Jackson J.V. Infect. Immun. 61:1993;1496.
23. See Experimental.